HYBRID EVENT: Join us in person in Tokyo, Japan or attend virtually from anywhere.
Ciliary body melanoma is a rare and potentially serious form of eye cancer that originates in the ciliary body, which is part of the eye's uvea. The ciliary body plays a crucial role in producing the fluid necessary for maintaining intraocular pressure. While ciliary body melanoma accounts for a small percentage of all eye cancers, it poses significant risks due to its potential for metastasis. Typically asymptomatic in its early stages, ciliary body melanoma often goes unnoticed until it reaches an advanced state. Common symptoms may include blurred vision, visual disturbances, and in some cases, eye pain. The diagnosis is usually confirmed through a comprehensive eye examination, imaging studies, and a biopsy if necessary. Treatment options for ciliary body melanoma depend on the size and location of the tumor. Approaches may include radiation therapy, surgical removal of the tumor, or, in some cases, enucleation (removal of the entire eye). Given the potential for metastasis, ongoing monitoring is crucial even after successful treatment. Prognosis varies based on the tumor's size, extent, and the success of treatment. Regular follow-up appointments with an ophthalmologist are essential to monitor for potential recurrence or metastasis. Ciliary body melanoma necessitates a multidisciplinary approach involving ophthalmologists, oncologists, and other specialists to provide comprehensive care and support for affected individuals. Early detection and timely intervention play a vital role in improving outcomes for those diagnosed with ciliary body melanoma.
